2000-18-77-6
IPOS reference

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 45/06

A1

(11) International Publication Number: **WO 99/17803**

(43) International Publication Date: 15 April 1999 (15.04.99)

(21) International Application Number: PCT/US98/20894

(22) International Filing Date: 2 October 1998 (02.10.98)

(30) Priority Data:
60/060,794 3 October 1997 (03.10.97) US

(71) Applicant *(for all designated States except US)*: CARY MEDICAL CORPORATION [US/US]; Suite 700, 7200 Wisconsin Avenue, Bethesda, MD 20814–3208 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: CARY, Douglas, D. [US/US]; 9903 Windy Hollow Road, Great Falls, VA 22066 (US).

(74) Agents: ADLER, Reid, G. et al.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).

(81) Designated States: AU, BR, CA, CN, JP, KR, SG, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: COMPOSITON FOR THE TREATMENT OF NICOTINE ADDICTION CONTAINING A NICOTINE RECEPTOR ANTAGONIST AND AN ANTI–DEPRESSANT OR ANTI–ANXIETY DRUG

(57) Abstract

The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long–term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti–depressant or an anti–anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti–anxiety drugs and anti–depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.